NIH & clinical-trial pipeline signals for ASTRAZENECA PLC (AZN)

Upstream (observed)
Clinical trial status (PHASE1) — A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

Upstream (observed)
Clinical trial status (n/a) — A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

Predicted downstream
SEC 8-K / press release (material trial update) (days–weeks)

Upstream (observed)
Clinical trial status (PHASE1) — A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

Upstream (observed)
Clinical trial status (n/a) — Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China

Predicted downstream
SEC 8-K / press release (material trial update) (days–weeks)

Upstream (observed)
Clinical trial status (n/a) — A Real-world Study Observing Treatment Patterns and Clinical Results for Patients in China With Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer.

Predicted downstream
SEC 8-K / press release (material trial update) (days–weeks)

Upstream (observed)
Clinical trial status (PHASE3) — A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

Upstream (observed)
Clinical trial status (PHASE3) — A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

Upstream (observed)
Clinical trial status (PHASE3) — A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

Upstream (observed)
Clinical trial status (PHASE3) — A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)